Company profile
Evome Medical Technologies Inc.
OTC: LNDZF · Healthcare · Medical - Devices
#442 of 1,418 Healthcare companies by revenue36th-percentile growth
EA Score
——FH —DQ 15GM —SS 45
v0.1 · 25/100 weight · pillars only
↑ workforce scale, operating margin · ↓ disclosure history, return on equity
Methodology →Revenue TTM
$35.5M
Rev growth YoY (TTM)
-16.8%
Net income (FY)
-$11.6M
Employees
195
as of 2026-08-30
Market cap
$6.0k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$46.4M62.6M CAD2023
Net income-$11.6M-15.6M CAD2023
Operating income-$4.1M-5.5M CAD2023
Total assets$36.5M48.3M CAD2023
Liabilities$33.5M44.3M CAD2023
Equity$3.0M4.0M CAD2023
Revenue trend
FY2022 – FY2023 · USD
FY22
FY22
FY22
FY22
FY22
FY22
FY23
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Evome Medical Technologies Inc.’s revenue?
Evome Medical Technologies Inc. booked $46.4M in FY2023 revenue, contracting 3.4% year over year — slower than 64% of Healthcare companies we track, at a -24.9% net margin.
Peers · Healthcare
Bioqual, Inc.65BGossamer Bio, Inc.24DShoulder Innovations, Inc.42DProtagonist Therapeutics, Inc.57CSepterna Inc50DTriSalus Life Sciences, Inc.44DNeighbors
Suffolk →Key facts
CEOChristopher Heath
SectorHealthcare
IndustryMedical - Devices
HeadquartersShirley, NY
ExchangeOTC: LNDZF
Employees195
IPO date2015-09-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.